89bio Inc.
Company Details
Status: Public
Employees: 11-50
Location:
San Francisco, California, United States of America
Type:
sample
Technology:
sample
sample
About: 89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Recent Phase 1b/2a data show BIO89-100 demonstrated a favorable safety and tolerability profile and robust reductions in liver fat and key lipid markers when dosed weekly or once every two weeks in patients with NASH. BIO89-100 is currently in a Phase 2 trial for the treatment of SHTG. 89bio is headquartered in San Francisco with operations in Herzliya, Israel.
Our culture is best described by our values:
• Always putting the patient first
• Operating with the highest integrity and ethical standards at all times
• Being authentic in all our transactions
• Acting as a team – collaborating, respecting and caring for one another
• Being entrepreneurial and passionate in our tasks
• Being scientific and rational in our thought process and decision-making
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
89bio Inc. | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.